In 2010, CRI researchers Drew Pardoll, M.D., Ph.D., Susan Topalian, M.D., and colleagues
completed a phase I study showing that a PD -1-specific monoclonal antibody induces frequent
tumor regressions in patients with advanced melanoma, renal cancer, lung cancer, and colon cancer with very low rates of toxicity.